NC-LENOVO
15.2.2024 15:01:34 CET | Business Wire | Press release
Today, Lenovo™ announced a strategic partnership with Anaconda® Inc., the leading provider of the world’s most popular artificial intelligence (AI), machine learning (ML) and data science platform, to empower Lenovo’s high performance data science workstations. The partnership will couple Lenovo’s trusted ThinkStation™ and ThinkPad™ workstation product portfolio heritage and leadership with Anaconda’s enterprise strengths for open-source leadership, security, and reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215334255/en/
Lenovo and Anaconda Announce Agreement to Accelerate AI Development and Deployment (Photo: Business Wire)
The rapidly evolving world of artificial intelligence, deep learning and generative AI is opening up new opportunities for businesses and data scientists. Much of the AI innovation taking place today is driven by open-source software and cloud-based solutions, with Python being a leading software language for AI applications. However, the data security risks associated with utilizing open-source software at an enterprise level, privacy concerns and often prohibitive cost of cloud-based AI solutions, is causing many organizations to rethink their approach to investment in AI development. With Intel®-powered Lenovo workstations architected with the latest generations of professional NVIDIA® GPUs built for large-language model fine-tuning, and the Anaconda Navigator’s ability to enable businesses to leverage open-source and AI with enhanced security, scale, and governance mechanisms in place, the partnership allows data scientists to create and deploy AI solutions with first class hardware and enterprise-grade AI software support within a more manageable investment framework.
Optimized for Intel platforms, Lenovo’s new generation of data science workstations deliver remarkable AI performance and is one of the world’s most powerful and scalable AI workstation portfolios. Planning for AI projects requires clear and thoughtful pathways to allocate the right hardware, software and skillsets to manage each stage of AI development. Lenovo workstations complement cloud-based AI solutions by acting as a bridge between local and cloud resources and aid data scientist flexibility and productivity. Lenovo’s full workstation portfolio includes highly configurable systems designed for nearly every AI workflow, industry or vertical, size and price point – all architected to drive the future of AI forward in an agile and cost-efficient way. From single CPU and GPU mobile workstations that are ideal for data input, collection and preparation, to the most powerful dual CPU and four GPU configurations for advanced AI workflows, Lenovo workstations with Anaconda Navigator offer protected “sandbox” environments to tackle the most complex AI solution development and deployment.
“With Lenovo’s trusted workstation leadership and Anaconda’s trusted leadership in open-source software support and reliability, the partnership is a perfect match,” said Rob Herman, Vice President and General Manager, Workstation and Client AI Group at Lenovo. “We’re excited to activate this partnership to aid data scientists in pushing forward the capabilities of AI with our premium workstations portfolio and Anaconda’s stellar open-source packages and repositories.”
Anaconda Navigator is available for download to use on current and future generation Lenovo Workstations.
“As artificial intelligence and machine learning models grow increasingly complex, high-performance workstations are imperative to empower data scientists with advanced capabilities,” said Chandler Vaughn, Chief Product Officer at Anaconda. “Lenovo's leadership in supplying optimized workstations, featuring robust GPUs, memory, and storage, positions them as an ideal collaborator for Anaconda and our Navigator desktop product. By jointly providing resilient hardware and trusted software tools, Lenovo and Anaconda present data scientists, AI developers, and AI engineers an unrivaled platform to freely explore emerging techniques in AI/ML. This symbiotic relationship enables organizations to push boundaries and accelerate innovations in artificial intelligence without technological constraints.”
For more information about Lenovo’s workstation portfolio, visit www.lenovo.com/workstations.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
About Anaconda
With more than 45 million users, Anaconda is the most popular operating system for AI providing access to the foundational open-source Python packages used in modern AI, data science and machine learning through a seamless platform. We pioneered the use of Python for data science, championed its vibrant community, and continue to steward open-source projects that make tomorrow’s innovations possible. Our enterprise-grade solutions enable corporate, research, and academic institutions around the world to harness the power of open-source for competitive advantage, groundbreaking research, and a better world. To learn more visit anaconda.com or connect on Twitter or LinkedIn.
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. Anaconda is a registered trademark owned by Anaconda, Inc. Intel is a trademark of Intel Corporation or its subsidiaries in the U.S. and/or other countries. NVIDIA is a trademark of NVIDIA Corporation. Inc. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215334255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom